Dr. Reddy’s launches generic of Librax in U.S.
The Hindu
The launch follows U.S. Food and Drug Administration approval for the product.
Dr. Reddy’s Laboratories has launched Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax in the U.S. market. The launch follows U.S. Food and Drug Administration (USFDA) approval for the product, which is indicated to control emotional and somatic factors in gastrointestinal disorders. The drug is also used as adjunctive therapy in treatment of peptic ulcer and irritable bowel syndrome. Sales in the U.S. of Librax brand and generic was approximately $105.9 million MAT for the most recent twelve months ending July 2021, the company said citing IQVIA Health numbers.More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












